ОПЫТ ПРИМЕНЕНИЯ ЭТАНЕРЦЕПТА ПРИ РАННЕМ ЮВЕНИЛЬНОМ АНКИЛОЗИРУЮЩЕМ СПОНДИЛОАРТРИТЕ
https://doi.org/10.15690/vsp.v11i2.233
Аннотация
Об авторах
А. Н. ФетисоваРоссия
Е. И. Алексеева
Россия
доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центра здоровья детей РАМН, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова
Т. М. Бзарова
Россия
Н. И. Тайбулатов
Россия
А. В. Старикова
Россия
А. В. Аникин
Россия
Г. А. Бекджанян
Россия
Список литературы
1. Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.
2. Nikishina I. P. Consilium medicum — Consilium medicum. 2006; 8 (2): 20–23.
3. Pepmueller P. H., Moore T. L. Juvenile onset spondylo arthropathies. Curr. Opin. Rheumatol. 2000; 12: 269–273.
4. Prier A. M. Spondyloarthropathies in childhood. Bailiere`s Clin. Rheumatol. 1998; 12: 287–307.
5. Burgos-Vargas R., Pacheco-Tena C., Vazquez-Mellado J. Juvenileonset spondyloarthropathies. Rheum. Dis. Clin. North. Am. 1997; 23: 569–598.
6. Nikishina I. P. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Prakticheskoe rukovodstvo po detskim boleznyam. Tom III. Pod obshchei red. V. F. Kokolinoi, A. G. Rumyantseva [Juvenile Ankylosing Spondylitis. Manual on Child Diseases. Volume 3. Edited by V. F. Kokolina, A. G. Rumyantsev]. Moscow, Medpraktika, 2004. pp. 620–649.
7. Kuz'mina N. N. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Detskaya revmatologiya. Rukovodstvo dlya vrachei. Pod red. A. A. Baranova, L. K. Bazhenovoi [Juvenile Ankylosing Spondylitis. Pediatric Rheumatology. Guideline. Edited by A. A. Baranov, L. K. Bazhenova]. Moscow, Meditsina, 2002. pp. 141–182.
8. Loginova E.Yu. Yuvenil'nyi artrit vo vzrosloi revmatologicheskoi klinike: kliniko-funktsional'naya kharakteristika i iskhody. Avtoref. dis. … kand. med. nauk [Juvenile Arthritis in Adult Rheumatologic Clinical Picture: Clinical and Functional Characteristics, Fate. Author’s abstract]. Moscow, 2001.
9. Bowyer S., Roettcher P. and the members of the Pediatric Rheumatology Database Research Group. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J. Rheumatol. 1996; 23: 1968–1974.
10. Towner S. R., Michet C. J. Jr, O’Fallon W. M., Nelson A. M. The epidemiology of juvenile arthritis in Rochester, Minnesota 1960– 1979. Arthritis Rheum. 1983; 26: 1208–1213.
11. Andersson Gare B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin. Exp. Rheumatol. 1999; 17: 367–374.
12. Manners P. J., Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J. Rheumatol. 2002; 29: 1520–1530.
13. Bochkova A. G. Consilium medicum — Consilium medicum. 2006; 8 (2).
14. Fearon U., Veale D. J. Pathogenesis of psoriatic arthritis. Clin. Exp. Dermatol. 2001; 26: 333–337.
15. Kalden J. R. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002; 4 (Suppl. 2): 534–540.
16. Mease P., Kivitz A. J., Burch F. X. et al. Etanercept treatment of psoriatic arthritis: sarety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.
17. Beutler B. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.
18. Granfors K., Marker-Hermann E., De Kayser F. The cutting edge of spondiloarthropathy research in the millennium. Arthritis Rheum. 2002; 46 (3): 606–613.
19. Mease P., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (Suppl. 2): 78–82.
20. Badokin V. C. Vrach — Physician. 2005; 5: 48–52.
21. Reed M. R., Taylor A. L. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008; 38 (10): 781–789.
22. Haibel H., Song I. H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice. Clin. Exp. Rheumatol. 2008; 26 (2): 247–252.
23. Braun J., Deodhar A., Dijkmans B. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008; 59 (9): 1270–1278.
24. Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009; 76 (1): 39–43.
25. Rumyantseva O. A. Nauchno-prakticheskaya revmatologiya — Reseach and practical rheumatology. 2006; 4: 11–19.
26. Kozlova A. L., Alekseeva E. I., Valieva S.I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 8 (2): 20–26.
27. Alekseeva E. I., Kozlova A. L., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2010; 9 (2): 23–31.
28. Alekseeva E. I., Alekseeva A. M., Valieva S. I. etc. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (2): 42–54.
29. Alekseeva E. I., Valieva S. I., Denisova R. V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–57.
30. Moreland L. W., Schiff M. H., Baumgarthner S. W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999; 130: 478–486.
31. Moreland L. W., Scott M. D., Baumgarther W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997; 337: 141–147.
32. Prince F. H., Twilt M., Ten Cate R. et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2008; 68 (5): 635–641.
33. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2008; 68 (4): 519–525.
34. Nielsen S., Ruperto N., Gerloni V. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.
35. Lovell D. J., Reiff A., Ilowite N. T. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
36. Robinson R. F., Nahata M. C., Hayes J. R. et al. Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept. Clin. Drug. Investig. 2003; 23 (8): 511–518.
37. Palazzi C., D’Angelo S., Cantini F. et al. Etanercept in spondylo arthropathies. Part I: current evidence of efficacy. Clin. Exp. Rheumatol. 2011; 29 (5): 858–64.
38. Navarro-Sarabia F., Fernandez-Sueiro J. L., Torre-Alonso J. C., Grata cos J. et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011; 50 (10): 1828–37.
39. Braun J., van der Horst-Bruinsma I. E., Huang F., BurgosVargas R. et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011; 63 (6): 1543–51.
Рецензия
Для цитирования:
Фетисова А.Н., Алексеева Е.И., Бзарова Т.М., Тайбулатов Н.И., Старикова А.В., Аникин А.В., Бекджанян Г.А. ОПЫТ ПРИМЕНЕНИЯ ЭТАНЕРЦЕПТА ПРИ РАННЕМ ЮВЕНИЛЬНОМ АНКИЛОЗИРУЮЩЕМ СПОНДИЛОАРТРИТЕ. Вопросы современной педиатрии. 2012;11(2):169-175. https://doi.org/10.15690/vsp.v11i2.233
For citation:
Fetisova A.N., Alexeeva E.I., Bzarova T.M., Taybulatov N.I., Starikova A.V., Anikin A.V., Bekdzhanyan G.A. USE OF ETANERCEPT IN JUVENILLE ANKYLOSING SPONDILLO-ARTHRITIS WITH EARLY ONSET. Current Pediatrics. 2012;11(2):169-175. (In Russ.) https://doi.org/10.15690/vsp.v11i2.233